Table 2.
Discounted costs, discounted quality-adjusted life expectancy, and incremental cost-effectiveness ratio for the base-case analysis (assuming biopsy-directed treatment adherence of 50%)
Strategy | Cost | Incremental cost | Effectiveness (QALYs) | Incremental effectiveness (QALYs) | ICER ($/QALY) |
---|---|---|---|---|---|
Usual care | $1,276 | -- | 17.943 | -- | -- |
See-and-treat | $1,692 | $417 | 17.949 | 0.006 | $70,774 |
QALY: quality-adjusted life-year, ICER: incremental cost-effectiveness ratio.